These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 12548577)

  • 1. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
    Smith MR
    Cancer; 2003 Feb; 97(3 Suppl):789-95. PubMed ID: 12548577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis during androgen deprivation therapy for prostate cancer.
    Smith MR
    Urology; 2002 Sep; 60(3 Suppl 1):79-85; discussion 86. PubMed ID: 12231056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
    Israeli RS; Ryan CW; Jung LL
    J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
    Ross RW; Small EJ
    J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
    J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer.
    Smith MR
    Cancer Metastasis Rev; 2002; 21(2):159-66. PubMed ID: 12465755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone health in men receiving androgen deprivation therapy for prostate cancer.
    Eastham JA
    J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of treatment-related osteoporosis in men with prostate cancer.
    Smith MR
    Cancer Treat Rev; 2003 Jun; 29(3):211-8. PubMed ID: 12787715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.
    Smith MR
    Drugs Aging; 2003; 20(3):175-83. PubMed ID: 12578398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
    Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
    Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy.
    Bernat MM; Pasini J; Mareković Z
    Coll Antropol; 2005 Dec; 29(2):589-91. PubMed ID: 16417166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
    J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
    Ryan CW; Huo D; Demers LM; Beer TM; Lacerna LV
    J Urol; 2006 Sep; 176(3):972-8; discussion 978. PubMed ID: 16890673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.